| 000 | 01810 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518100711.0 | ||
| 264 | 0 | _c20210401 | |
| 008 | 202104s 0 0 eng d | ||
| 022 | _a1523-1747 | ||
| 024 | 7 |
_a10.1016/j.jid.2020.04.006 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStegemann, Agatha | |
| 245 | 0 | 0 |
_aThe α7 Nicotinic Acetylcholine Receptor: A Promising Target for the Treatment of Fibrotic Skin Disorders. _h[electronic resource] |
| 260 |
_bThe Journal of investigative dermatology _c12 2020 |
||
| 300 |
_a2371-2379 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenoviridae _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBleomycin _xtoxicity |
| 650 | 0 | 4 |
_aBridged Bicyclo Compounds, Heterocyclic _xpharmacology |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCollagen _xmetabolism |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 |
_aFibroblasts _xdrug effects |
| 650 | 0 | 4 | _aFibrosis |
| 650 | 0 | 4 |
_aGenetic Vectors _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aPrimary Cell Culture |
| 650 | 0 | 4 |
_aQuinuclidines _xpharmacology |
| 650 | 0 | 4 |
_aReceptor, Transforming Growth Factor-beta Type I _xgenetics |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xchemically induced |
| 650 | 0 | 4 |
_aSkin _xcytology |
| 650 | 0 | 4 |
_aalpha7 Nicotinic Acetylcholine Receptor _xagonists |
| 700 | 1 | _aFlis, Damian | |
| 700 | 1 | _aZiolkowski, Wieslaw | |
| 700 | 1 | _aDistler, Jörg H W | |
| 700 | 1 | _aSteinbrink, Kerstin | |
| 700 | 1 | _aBöhm, Markus | |
| 773 | 0 |
_tThe Journal of investigative dermatology _gvol. 140 _gno. 12 _gp. 2371-2379 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jid.2020.04.006 _zAvailable from publisher's website |
| 999 |
_c30901228 _d30901228 |
||